Stockscreener 앱 받기
10.41
1.33%
-0.14
시장 영업 전:
10.40
-0.010
-0.10%
Viatris Inc 주식(VTRS)의 최신 뉴스
What high frequency data says about Viatris Inc.2025 Trading Volume Trends & Daily Growth Stock Investment Tips - Newser
How to use a screener to detect Viatris Inc. breakoutsBear Alert & Daily Price Action Insights - Newser
Market reaction to Viatris Inc.’s recent newsWeekly Profit Analysis & Real-Time Sentiment Analysis - Newser
Key resistance and support levels for Viatris Inc.July 2025 Fed Impact & Daily Chart Pattern Signal Reports - Newser
Using data models to predict Viatris Inc. stock movementJuly 2025 Momentum & Short-Term Swing Trade Alerts - Newser
Advanced analytics toolkit walkthrough for Viatris Inc.Market Activity Summary & Safe Entry Point Alerts - Newser
Stock Analysis | Viatris OutlookA Stock at a Crossroads Between Weak Technicals and Mixed Fundamentals - AInvest
Full technical analysis of Viatris Inc. stockJuly 2025 Pullbacks & Proven Capital Preservation Tips - Newser
Should you hold or exit Viatris Inc. nowWeekly Profit Report & Advanced Swing Trade Entry Alerts - Newser
What moving averages say about Viatris Inc.Market Movement Recap & Risk Controlled Stock Alerts - Newser
Viatris Inc. shares fall 1.13% intraday as Theravance Biopharma completes enrollment in pivotal Phase 3 trial. - AInvest
Saudi Arabia Generic Drugs Market Outlook and Company Analysis 2025-2033 Featuring Teva, Viatris, Sa - PharmiWeb.com
Viatris Inc. (VTRS) Stock Analysis: Navigating a 7.31% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
How to track smart money flows in Viatris Inc.Portfolio Update Report & Weekly Breakout Opportunity Watchlist - Newser
How to build a dashboard for Viatris Inc. stockJuly 2025 Summary & Comprehensive Market Scan Reports - Newser
Viatris' Strategic Leadership Realignment and Long-Term Growth Potential - AInvest
Ex-Dividend Reminder: Evergy, Viatris and CRH - Nasdaq
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment - FinancialContent
Viatris Inc. Appoints Andrew Enrietti as Chief Administrative and Transformation Officer - MarketScreener
Night Vision Disturbances Market to Experience Notable Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Lead Plaintiff Appointed in Viatris Class Action — Here’s How You Can Recover Your Losses - TradingView
Viatris names Andrew Enrietti as chief administrative officer - Investing.com
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer - Viatris
Viatris Inc. shares fall 1.79% premarket after Jefferies adjusted price target to $14. - AInvest
Viatris Inc Faces Headwinds: Diminished Financial Strength, Growth, and Valuation Rankings - AInvest
Jefferies Adjusts Price Target on Viatris to $14 From $13, Maintains Buy Rating - MarketScreener
What are the risks of holding Viatris Inc.Weekly Stock Summary & Stock Market Timing Techniques - classian.co.kr
Viatris Inc. Consolidation Zone May Signal Accumulation2025 Market WrapUp & High Conviction Investment Ideas - newsyoung.net
David Einhorn's Greenlight Capital Boosts Fluor Corp, Exits Viatris, Peloton, and Kyndryl - AInvest
Trump EO to bolster stockpile of active pharmaceutical ingredients for drugs - Seeking Alpha
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3 - insights.citeline.com
Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth - GlobeNewswire Inc.
Day 5 of Gains Streak for Viatris Stock with 19% Return (vs. -14% YTD) [8/13/2025] - Trefis
CEO Makes Bold Move with Major Viatris Stock Purchase - TipRanks
Viatris CEO Smith buys $219k in company stock By Investing.com - Investing.com Nigeria
Viatris CEO Smith buys $219k in company stock - Investing.com India
Viatris CEO Smith Buys 22K Shares at $9.99/Share on August 12, 2023. - AInvest
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - Yahoo Finance
VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds - ca.finance.yahoo.com
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know - Yahoo Finance
Viatris first to win US approval for generic Venofer - The Pharma Letter
Brufen Maker Viatris Fails To Halt Rival's 'Brisen' TM Quest - Law360
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - BioSpace
Why Viatris (VTRS) Is Up 10.3% After Beating Q2 Estimates and Securing FDA Generic Win - simplywall.st
Ampicillin Market Driven by Rising Bacterial Infections - openPR.com
Sector Update: Health Care - MarketScreener
Merz Asks UPC To Bar Viatris Generic MS Drug - Law360
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Viatris Stock Rises 3% After FDA Approval for Generic Iron Sucrose Injection - AInvest
Why Viatris (VTRS) Stock Is Up Today - Yahoo Finance
1.73%
2.13%
자본화:
|
볼륨(24시간):